A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

Also called NCT02954692

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 112 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02954692
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02954692. Allocation not applicable; no masking; primary purpose treatment. Start 2016-11-30 (registry gives no type); primary completion 2017-12-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
Acronym
EASE
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
INSULIN GLARGINE (U300)
Intervention (Drug)
metformin
Intervention (Drug)
sulfonylurea
Intervention (Drug)
meglitinides
Intervention (Drug)
thiazolidinediones
Intervention (Drug)
alpha-glucosidase inhibitors
Intervention (Drug)
GLP1 Receptor Agonist
Intervention (Drug)
Dipeptidyl peptidase-IV (DPP-IV) inhibitors
Intervention (Drug)
Sodium-glucose transport-2 (SGLT-2) inhibitors
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02954692
Content hash
57d0f73f581d77814046498c65c5504f77081739c3b1c6d06d1ffe8fca2f6145